Resultado de búsqueda
3 de sept. de 2021 · 1/ 👻 AKI in patients with a kidney transplant can sometimes be “SCARI” 🧵 Let’s talk about an approach I recently learned to some common causes of late (>3 months) allograft dysfunction to overcome the fear together #Tweetorial #NephTwitter
23 de jun. de 2023 · Curious about artificial implantable organs? We're excited to hear from Dr. Shuvo Roy, who is helping shape the future of this kidney innovation through @KidneyProject @UCSF and @VUMCKidney! Join us for the latest at this year's Global Summit! Register: http://bit.ly/AAKPGlobal . 23 Jun 2023 22:00:28
2 de mar. de 2023 · Atypical hemolytic uremic syndrome (aHUS) is a devastating form of thrombotic microangiopathy (TMA) predominantly involving the kidney. 1 Untreated, it leads to end-stage renal disease in up to 2 out of 3 affected patients, shortly after onset or following relapses. 2-4 The unraveling of the pathogenic mechanisms underlying aHUS, namely an overactivation of the complement alternative pathway ...
Eculizumab has been used pre-emptively for renal transplant in aHUS and prophylactically after renal transplantation (43,54,69). The best results in terms of normalizing renal function were obtained when eculizumab was given as soon as possible after onset of aHUS . Eculizumab also successfully treated skin necrosis in aHUS .
Abstract. Rationale and objective: Patients with atypical hemolytic uremic syndrome (aHUS) have long been considered ineligible for kidney transplantation (KTx) in several centers due to the high risk of disease recurrence, graft loss and life-threatening complications. The availability of Eculizumab (ECU) has now overcome this problem.
13 de ago. de 2020 · Abstract. Background. Kidney transplantation (KTx) is a strong trigger for the development of either recurrent or de novo atypical haemolytic uraemic syndrome (aHUS). According to previous studies, eculizumab (ECU) is effective for prophylaxis and for treatment of recurrence. Methods.
27 de jun. de 2019 · Background: Kidney transplantation in patients with atypical hemolytic uremic syndrome (aHUS) is frequently complicated by recurrence, resulting in thrombotic microangiopathy in the renal allograft and graft loss. We aimed to assess the use of eculizumab in the prevention and treatment of aHUS recurrence after kidney transplantation.
